Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Stemline Therapeutic (STML)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 653,965
  • Shares Outstanding, K 43,685
  • Annual Sales, $ 500 K
  • Annual Income, $ -85,020 K
  • 60-Month Beta 1.20
  • Price/Sales 1,279.10
  • Price/Cash Flow N/A
  • Price/Book 5.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.47
  • Number of Estimates 5
  • High Estimate -0.38
  • Low Estimate -0.54
  • Prior Year -0.66
  • Growth Rate Est. (year over year) +28.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.55 +10.48%
on 04/25/19
16.35 -8.44%
on 05/10/19
+0.72 (+5.05%)
since 04/24/19
3-Month
10.57 +41.63%
on 02/28/19
16.35 -8.44%
on 05/10/19
+3.37 (+29.05%)
since 02/22/19
52-Week
7.82 +91.43%
on 12/21/18
20.55 -27.15%
on 06/05/18
-4.68 (-23.82%)
since 05/24/18

Most Recent Stories

More News
Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at Upcoming EHA Annual Congress

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that ELZONRIS (tagraxofusp)...

STML : 14.97 (+2.25%)
Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at the Upcoming ASCO Annual Meeting

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that ELZONRIS (tagraxofusp)...

STML : 14.97 (+2.25%)
Stemline Therapeutics (STML) Reports Q1 Loss, Tops Revenue Estimates

Stemline Therapeutics (STML) delivered earnings and revenue surprises of -8.96% and 93.82%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

STML : 14.97 (+2.25%)
Stemline Therapeutics: 1Q Earnings Snapshot

NEW YORK (AP) _ Stemline Therapeutics Inc. (STML) on Friday reported a loss of $27.4 million in its first quarter.

STML : 14.97 (+2.25%)
Stemline Therapeutics Reports First Quarter 2019 Financial Results

-- Net revenue for ELZONRIS was $5.05 million for the first quarter

STML : 14.97 (+2.25%)
Stemline Therapeutics to Host Conference Call on First Quarter 2019 Financial Results on May 10, 2019

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that the company...

STML : 14.97 (+2.25%)
Repligen Corp is Among the Companies in the Biotechnology Industry with the Best Relative Performance (RGEN , LXRX , STML , DVAX , CHRS )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

LXRX : 5.92 (+2.78%)
STML : 14.97 (+2.25%)
RGEN : 68.86 (+2.73%)
Stemline Therape is Among the Companies in the Biotechnology Industry with the Best Relative Performance (STML , BCRX , CCXI , ALXN , PTLA )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

STML : 14.97 (+2.25%)
BCRX : 3.32 (-6.21%)
CCXI : 11.71 (+0.95%)
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (PGNX , STML , CHRS , BPMC , BCRX )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

PGNX : 4.54 (+4.85%)
STML : 14.97 (+2.25%)
CHRS : 20.36 (unch)
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (MNTA , SGEN , STML , NVTA , EPZM )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

STML : 14.97 (+2.25%)
MNTA : 12.26 (-1.05%)
SGEN : 69.14 (+1.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade STML with:

Business Summary

Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric...

See More

Key Turning Points

2nd Resistance Point 15.54
1st Resistance Point 15.26
Last Price 14.97
1st Support Level 14.44
2nd Support Level 13.91

See More

52-Week High 20.55
Fibonacci 61.8% 15.69
Last Price 14.97
Fibonacci 50% 14.18
Fibonacci 38.2% 12.68
52-Week Low 7.82

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar